617245-62-2Relevant articles and documents
NOVEL BENZAMIDE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS
-
Page 52, (2008/06/13)
Novel compounds of Formula I which modulate MCH activity are disclosed, in which A is a linker, Ar, is an aryl or heteroaryl group; R1 is hydrogen or a lower alkoxy group; Q together with the carbonyl forms an amide group, which is further substituted with an amine group; R5 is hydrogen, halogen atoms, alkoxy groups, hydroxy, alkylamino groups, dialkylamino groups, hydroxylalkyl groups, carboxamido groups, acylamido groups, acyl groups,-CHO, nitrile, alkyl, alkenyl or alkynyl groups,-SCH3, partially or fully fluorinated alkyl, alkoxy or thioalkoxy groups such as-CH2CF3,-CF2CF3,-CF3,-OCF3,-SCF3;-SO2NH2,-SO2NHAlk,-SO2NAlk2,-SO2AIk; R8 is hydrogen, halogen atoms, alkyl, alkenyl or alkynyl groups, cycloalkyl groups, alkylcycloalkyl groups, alkoxy groups, dialkylamino groups,-CONHAIk,-CONAIk2,-NHCO-Alk,-CO-Alk,-SCH3, partially or fully fluorinated alkyl, alkoxy or thioalkoxy groups such as-CH2CF3,-CF2CF3,-CF3,-OCF3,-SCF3; X is H, F, Cl, Br, I,-SCH3, partially or fully fluorinated alkyl, alkoxy or thioalkoxy groups such as-CH2CF3,-CF2CF3,-CF3,-OCF3,-SCF3; OCH3 or lower alkyl or alkenyl group; and which are useful in the treatment or prevention of e.g. obesity, depression, diabetes, bulimia etc.